Apogee Therapeutics, Inc. (NASDAQ:APGE) Shares Bought by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) by 4.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 23,835 shares of the company’s stock after acquiring an additional 931 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. owned 0.05% of Apogee Therapeutics worth $1,078,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in APGE. Janus Henderson Group PLC grew its holdings in Apogee Therapeutics by 141.7% during the fourth quarter. Janus Henderson Group PLC now owns 1,135,100 shares of the company’s stock worth $51,455,000 after acquiring an additional 665,543 shares during the period. Jefferies Financial Group Inc. boosted its position in shares of Apogee Therapeutics by 140.4% during the 4th quarter. Jefferies Financial Group Inc. now owns 887,497 shares of the company’s stock worth $40,204,000 after purchasing an additional 518,300 shares in the last quarter. Granahan Investment Management LLC grew its stake in shares of Apogee Therapeutics by 1.2% during the 4th quarter. Granahan Investment Management LLC now owns 92,854 shares of the company’s stock worth $4,206,000 after purchasing an additional 1,097 shares during the period. Deutsche Bank AG increased its holdings in shares of Apogee Therapeutics by 50.9% in the 4th quarter. Deutsche Bank AG now owns 31,739 shares of the company’s stock valued at $1,438,000 after purchasing an additional 10,709 shares in the last quarter. Finally, Driehaus Capital Management LLC increased its holdings in shares of Apogee Therapeutics by 2.8% in the 4th quarter. Driehaus Capital Management LLC now owns 2,605,310 shares of the company’s stock valued at $118,021,000 after purchasing an additional 71,703 shares in the last quarter. 79.04% of the stock is currently owned by institutional investors and hedge funds.

Apogee Therapeutics Price Performance

Shares of NASDAQ APGE opened at $39.48 on Monday. The firm’s 50-day moving average is $36.74 and its two-hundred day moving average is $40.42. The company has a market capitalization of $1.82 billion, a PE ratio of -16.31 and a beta of 1.70. Apogee Therapeutics, Inc. has a 12-month low of $26.20 and a 12-month high of $63.50.

Apogee Therapeutics (NASDAQ:APGE) last posted its earnings results on Monday, May 12th. The company reported ($0.95) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.19) by $0.24. On average, analysts forecast that Apogee Therapeutics, Inc. will post -3.09 EPS for the current fiscal year.

Insider Activity

In related news, insider Carl Dambkowski sold 1,590 shares of the firm’s stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $30.48, for a total transaction of $48,463.20. Following the sale, the insider now owns 251,033 shares in the company, valued at approximately $7,651,485.84. This trade represents a 0.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Michael Thomas Henderson sold 10,000 shares of the business’s stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $30.15, for a total value of $301,500.00. Following the completion of the transaction, the chief executive officer now owns 1,292,987 shares of the company’s stock, valued at $38,983,558.05. This trade represents a 0.77% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 18,175 shares of company stock worth $587,191 over the last three months. 42.77% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several research analysts have weighed in on the stock. Citigroup initiated coverage on shares of Apogee Therapeutics in a research report on Thursday, March 13th. They set a “buy” rating and a $95.00 target price on the stock. Wedbush restated an “outperform” rating and issued a $90.00 price target on shares of Apogee Therapeutics in a report on Tuesday, March 11th. Finally, Guggenheim reaffirmed a “buy” rating on shares of Apogee Therapeutics in a research note on Monday, February 10th. Five analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $94.60.

About Apogee Therapeutics

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.